A major role of insulin in promoting obesity-associated adipose tissue inflammation by Pedersen, David J. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2015-05-01 
A major role of insulin in promoting obesity-associated adipose 
tissue inflammation 
David J. Pedersen 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cellular and Molecular Physiology Commons, Endocrinology Commons, and the Molecular 
Biology Commons 
Repository Citation 
Pedersen DJ, Guilherme A, Danai LV, Heyda L, Matevossian A, Cohen JL, Nicoloro SM, Straubhaar JR, Noh 
HL, Jung D, Kim JK, Czech MP. (2015). A major role of insulin in promoting obesity-associated adipose 
tissue inflammation. Open Access Articles. https://doi.org/10.1016/j.molmet.2015.04.003. Retrieved 
from https://escholarship.umassmed.edu/oapubs/2705 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
A major role of insulin in promoting obesity-
associated adipose tissue inﬂammation
David J. Pedersen 1,3, Adilson Guilherme 1,3, Laura V. Danai 1, Lauren Heyda 1, Anouch Matevossian 1,
Jessica Cohen 1, Sarah M. Nicoloro 1, Juerg Straubhaar 1, Hye Lim Noh 1,2, DaeYoung Jung 1,2,
Jason K. Kim 1,2, Michael P. Czech 1,*
ABSTRACT
Objective: Adipose tissue (AT) inﬂammation is associated with systemic insulin resistance and hyperinsulinemia in obese rodents and humans.
A longstanding concept is that hyperinsulinemia may promote systemic insulin resistance through downregulation of its receptor on target
tissues. Here we tested the novel hypothesis that insulin also impairs systemic insulin sensitivity by speciﬁcally enhancing adipose inﬂammation.
Methods: Circulating insulin levels were reduced by about 50% in diet-induced and genetically obese mice by treatments with diazoxide or
streptozotocin, respectively. We then examined AT crown-like structures, macrophage markers and pro-inﬂammatory cytokine expression in AT.
AT lipogenesis and systemic insulin sensitivity was also monitored. Conversely, insulin was infused into lean mice to determine its affects on the
above parameters.
Results: Lowering circulating insulin levels in obese mice by streptozotocin treatment decreased macrophage content in AT, enhancing insulin
stimulated Akt phosphorylation and de novo lipogenesis (DNL). Moreover, responsiveness of blood glucose levels to injected insulin was improved
by streptozotocin and diazoxide treatments of obese mice without changes in body weight. Remarkably, even in lean mice, infusion of insulin
under constant euglycemic conditions stimulated expression of cytokines in AT. Consistent with these ﬁndings, insulin treatment of 3T3-L1
adipocytes caused a 10-fold increase in CCL2 mRNA levels within 6 h, which was blocked by the ERK inhibitor PD98059.
Conclusion: Taken together, these results indicate that obesity-associated hyperinsulinemia unexpectedly drives AT inﬂammation in obese
mice, which in turn contributes to factors that suppress insulin-stimulated adipocyte DNL and systemic insulin sensitivity.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Current evidence indicates that chronic low-grade inﬂammation in
adipose tissue (AT) may be a contributing mechanism in obesity-
induced insulin resistance and type 2 diabetes [1e10]. Many groups
have observed increased pro-inﬂammatory cytokine and chemokine
production as well as elevated macrophage and other immune cell
content in the AT of obese rodents and humans [11e13]. The pro-
inﬂammatory state of AT in obesity is considered a key event driving
local and systemic metabolic dysfunction [2,4,12,14]. Consistent with
this notion, deletion or silencing of pro-inﬂammatory genes has been
demonstrated to enhance insulin action in AT and improve whole-body
glucose homeostasis in obese animal models [12,15]. Evidence has
also been presented that AT inﬂammation can be a beneﬁcial aspect of
adipose remodeling and responsiveness to obesity [16e19], sug-
gesting that AT inﬂammation may have multiple roles. Nonetheless, at
later stages of obesity, a predominant deleterious effect of AT
inﬂammation on adipose insulin sensitivity and systemic glucose
tolerance seems apparent [20].
Impaired adipocyte responsiveness to insulin in obesity is thought to
secondarily affect whole body metabolism by limiting adipose tissue’s
ability to store lipid and sequester fatty acids away from peripheral
tissues. It is also proposed that adipocyte de novo lipogenesis (DNL),
which generates fatty acids from glucose, produces endogenous lipid
ligands such as hydroxy fatty acid esters [21] and palmitoleate [22]
that enhance local and systemic glucose metabolism [21e23].
These results suggest that the insulin-sensitive AT DNL pathway may
play a critical role in maintaining tightly controlled whole body glucose
homeostasis and high insulin sensitivity [21,22]. However, the activity
of the DNL pathway and the genes associated with DNL are strongly
repressed in obese, insulin-resistant AT of both humans and rodents
[23e31]. The chronically elevated AT inﬂammatory state observed in
obesity may be a key factor in this inhibition of AT-DNL. Consistent with
this concept, cytokine-mediated suppression of PPARg, SREBP1c and
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its lipogenic gene targets, such as GLUT4 and fatty acid synthase
(Fasn), has been demonstrated in AT in vivo, as well as in cultured
adipocytes in vitro [32e37]. Thus, AT inﬂammation may contribute to
the suppression of glucose tolerance and systemic insulin sensitivity
through its downregulation of insulin action and DNL in adipocytes.
In spite of the many studies that document the expansion of macro-
phages and other immune cell types within AT in obesity, the initiating
factors in this process are not identiﬁed. Adipocytes express cytokines
such as CCL2 and TNF-a, but at seemingly lower levels than do im-
mune cells, and the role of these adipocyte factors is unclear. Another
possible agent that might contribute to inducing AT inﬂammation is
insulin itself. Obesity is usually associated with hyperinsulinemia and
studies in humans have suggested a link between hyperinsulinemia
and AT inﬂammation. These include reports of increased pro-
inﬂammatory cytokine expression and macrophage inﬁltration into
AT during a hyperinsulinemic-euglycemic clamp [38e43]. Further-
more, increased pro-inﬂammatory activity has also been reported in
human AT from subjects following insulin therapy [44]. However,
whether obesity-associated hyperinsulinemia promotes AT inﬂam-
mation and the mechanism by which this occurs remains to be fully
elucidated. Here we report that a reduction in circulating insulin levels
in obese mice causes a marked decrease in AT macrophage expansion
and attenuated pro-inﬂammatory AT cytokine/chemokine expression.
Furthermore, this reduction in circulating insulin improved AT-DNL
activity and insulin signaling in AT as well as systemic insulin sensi-
tivity in obese mice. These results indicate that hyperinsulinemia
contributes substantially to driving AT inﬂammation in obesity, leading
to worsening whole-body glucose tolerance and insulin resistance.
2. MATERIAL AND METHODS
2.1. Subject samples and microarray study
Samples were obtained from 36 adult patients, undergoing laparo-
scopic Roux-en-Y gastric bypass surgery as described [13]. The de-
mographic data including age, gender, height, weight, calculated BMI
and fasting glucose and insulin levels were recorded at the time of
gastric bypass surgery. All subjects provided written informed consent
before taking part in the study. The study was approved by the Uni-
versity of Massachusetts Medical School Institutional Review Board.
Adipose tissue samples were taken from lower abdominal wall (sub-
cutaneous) and greater omentum (visceral) and snap frozen in liquid
nitrogen. Total RNA was isolated from human tissues by homogenizing
the frozen tissue in TRIzol (Invitrogen, Carlsbad, CA). Affymetrix Gen-
eChip Human Genome U133 Plus 2.0 arrays were prepared as pre-
viously described [13]. GeneChip Expression Arrays for each gene were
analyzed as described [13].
2.2. Animal studies
We obtained 4-week old male C57BL/6J (WT) and B6.V-Lepob/J (ob/
ob) mice from Jackson Laboratory. Mice were housed on a 12 h light/
dark schedule and had free access to water and food, except when
indicated. WT mice were fed a HFD (Research Diets) that contained
60% calories from lipids, in the absence (D12492) or presence of
1.125 mg/kg diazoxide (D12121501). All procedures involving animals
were approved by the Institutional Animal Care and Use Committee at
the University of Massachusetts Medical School. Glucose and insulin
tolerance tests were performed on ob/ob mice as indicated. Glucose
(1 g/kg) and insulin (1 IU/kg) were administrated by intraperitoneal
(i.p.) injection. Blood samples were withdrawn from the tail vein at the
indicated times, and glycemia was determined using a Breeze 2
glucose meter (Bayer and alpha-trak). Plasma insulin and C-peptide
levels were measured with Millipore insulin ELISA and ALPCO Mouse
C-peptide ELISA, respectively.
2.3. Hyperinsulinemic-euglycemic clamp studies
The clamp study was performed at the UMass Mouse Metabolic
Phenotyping Center. Six-week-old wild type (WT) mice were subjected
to an overnight fast and a 2-h hyperinsulinemic-euglycemic clamp was
conducted in awake mice with a primed and continuous infusion of
human insulin (150 mU/kg body weight priming followed by 4
mU$kg1 min1; Humulin, Eli Lilly). During the clamp, 20% glucose
was infused at variable rates to maintain euglycemia [45]. At the end of
the study, mice were anesthetized, and tissues were taken for total
RNA extraction and quantitative RT-PCR analysis.
2.4. Histology
Epididymal white adipose and pancreas tissues were dissected and
ﬁxed by immersion in 10% neutral buffered formalin (Sigma, St. Louis,
MO) for 12 h, dehydrated, cleared, and then embedded in parafﬁn.
Sections (7 mm) were stained with hematoxylin and eosin or with anti-
F4/80 antibody to assess morphology or detect macrophage and
crown-like structures in AT. Pancreatic islets were stained with insulin
antibody (Cell Signaling, Danvers, MA), as indicated.
2.5. Reagents
Streptozotocin, diazoxide, bovine insulin, FA-free BSA, D-glucose, so-
dium pyruvate, sodium acetate, anti-tubulin and anti-beta-actin anti-
body were purchased from SigmaeAldrich. PD98059 and MK2206
were from EMD Millipore and Selleckchem respectively. 14C-U-glucose
(250 mCi/mL) was purchased from Perkin Elmer. Antibodies against
ATP-citrate lyase (Acly), fatty acid synthase (Fasn), CCL2, TNFa, Akt,
phospho-Akt (ser473) and insulin receptor were from Cell Signaling
Technology (Danvers, MA)
2.6. Cell culture
3T3-L1 ﬁbroblasts were grown and differentiated into adipocytes as
previously described [46]. Brieﬂy, 3T3-L1 ﬁbroblasts were grown to
conﬂuence in complete media (high glucose (25 mM) DMEM con-
taining 10% fetal bovine serum, 50 units/mL penicillin and 50 mg/mL
of streptomycin). Two days after conﬂuence, differentiation media
(DMEM containing 0.25 mM dexamethasone, 0.5 mM 1-methyl-3-
isobutylxanthine, and 107 M insulin) was added. Three days post-
induction, differentiation media was replaced by complete media
without insulin. On day 5, media was again changed with fresh
complete media. On the seventh day after differentiation, media was
added, adipocytes were pretreated with PD98059, MK2206 or DMSO
vehicle for 30 min followed by treatment with 1 mM or 100 nM insulin,
as stated in the Figure legends, for the indicated period of time.
2.7. Real-time quantitative RT-PCR
Total RNA was extracted from 3T3-L1 adipocytes or mouse tissues
using TRIzol Reagent Protocol (Invitrogen) following the manufacturer’s
instructions. cDNA was synthesized from 1 ug of total RNA using
iScript cDNA Synthesis Kit (BioRad). Quantitative RT-PCR was per-
formed using iQ SybrGreen supermix and analyzed as previously
described [47,48]. 36B4, Hprt and Gapdh served as controls for
normalization
2.8. Immunoblotting
For experiments on ex-vivo insulin treatment, adipose tissue explants
were incubated in DMEM media supplemented with 0.5 mM glucose,
2 mM sodium pyruvate and 2 mM glutamine, in the absence or
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presence of 1 mM insulin for 45 min. Adipose tissue explants were then
homogenized and total cell lysate immunoblotted with the indicated
antibodies. Total cell lysates were resolved by SDS-PAGE and elec-
trotransferred to nitrocellulose membranes. Membranes were incu-
bated with the indicated antibodies overnight at 4 C. Immunoblots
were washed with TBST (0.2% Tween 20 in Tris-Buffered saline),
incubated with horseradish peroxidase anti-mouse or anti-rabbit
secondary antibody and visualized using enhanced chemilumines-
cent substrate kit (Perkin Elmer).
2.9. Ex vivo lipogenesis
The incorporation of the various radioactive substrates into TG and FA
was measured as previously described [49]. Brieﬂy, adipose tissue
explants were incubated with labeling media containing 2.50% FA free
BSA, 1% (v/v) Pen/Strep, 0.5 mM D-Glucose, 0.5 mM Sodium Acetate,
2 mM sodium pyruvate, 2 mM glutamine, 2 mCi/mL 14C-U-glucose.
Insulin at 1 mM was added to insulin-stimulated conditions. Adipose
tissue explants were incubated at 37 C in a humidiﬁed incubator (5%
CO2) for 4.5 h before lipid extraction. All metabolic processes were
stopped by the addition of modiﬁed Dole’s extraction mixture (80 mL
isopropanol, 20 mL hexane, 2 mL of 1N H2SO4) [50]. TG was extracted
with hexane, washed and evaporated. Incorporation of 14C-glucose
into FA of TG was determined by evaporating neutral lipids, adding
1 mL KOH-ethanol (20 mL of 95% ethanol, 1 mL water, 1 mL saturated
KOH) and heating samples to 80 C for 1 h. The mixture was acidic to
ensure complete saponiﬁcation. Addition of hexane allowed hydro-
phobic separation, which was evaporated and counted by liquid
scintillation.
2.10. Statistical analysis
Differences between groups were examined for statistical signiﬁcance
using the two-tailed Student’s test or analysis of variance (ANOVA)
tests. The data are presented as means  SE. P values 0.05 were
considered signiﬁcant.
3. RESULTS
3.1. AT inﬂammation highly correlates with hyperinsulinemia
To assess whether the expression of AT pro-inﬂammatory markers
correlate with the circulating insulin levels in obese humans, we
examined plasma insulin levels and cytokine and chemokine mRNA
expression levels in visceral adipose tissue from obese subjects.
Samples from 36 individuals with a range of BMI values showed a
positive correlation between circulating insulin concentrations and
increased AT inﬂammation, as assessed by CCL2, IL6, Tnfa and IL1b
mRNA (Figure 1A). The strong positive relationship between insulin and
the above AT chemokine and cytokine mRNAs was independent of BMI
(Figure 1A). These data indicate that the degree of AT inﬂammation
strongly correlates with increasing circulating levels of insulin in obese
subjects over a broad range of body weights.
To conﬁrm that the AT inﬂammation state correlates with circulating
insulin levels in mice, we investigated the relationship between the
increased expression levels of pro-inﬂammatory genes in AT and the
plasma insulin concentrations in both diet- and genetically-induced
obese mice. As depicted in Figure 1B, the degree of AT inﬂamma-
tion, determined by the expression of CCL2, IL6, IL1b and Tnfa mRNA
levels, positively correlates with the increase in plasma insulin con-
centrations induced by 1e4 weeks of high fat diet (HFD) feeding.
Similarly, the increase in Cd11c þ macrophage content in AT strongly
correlates with the degree of hyperinsulinemia induced by short-term
HFD-feeding (Figure 1C).
To further investigate the relationship between hyperinsulinemia and
AT inﬂammation, we examined the body weight, insulin levels, AT
inﬂammation, glucose and insulin tolerance of WT and ob/ob mice, a
well-known hyperinsulinemic, genetically obese mouse model, be-
tween 4 and 11 weeks of age. As depicted in Figure 2A, ob/ob mice
displayed a modest increase in body weight (WT vs. ob/ob) at 5 wks of
age and exhibited signiﬁcant glucose intolerance (Figure 2B).
Consistent with an early onset of insulin resistance (Figure 2C), 5 wk
old ob/ob mice displayed about a 15-fold increase in circulating insulin
levels (Figure 2D) compared to age-matched WT littermates at 5, 7,
and 11 weeks of age. These results conﬁrm that hyperinsulinemia,
glucose intolerance and insulin resistance occur at an early age in ob/
ob mice despite only a slight increase in body weight.
To examine whether the early onset of hyperinsulinemia in ob/ob mice
was associated with increased pro-inﬂammatory gene expression in
AT, we examined mRNA levels of inﬂammatory markers by quantitative
RT-PCR. As shown in Figure 2E, the expression levels of Tnfa, CCL2,
IL6, IL1b and the macrophage marker Emr1 were all signiﬁcantly
augmented in subcutaneous and epididymal adipose depots from 5-
week old ob/ob mice. Although the increase in pro-inﬂammatory
gene expression was detected in both adipose depots, the quantita-
tive changes were signiﬁcantly greater in the epididymal AT. In
contrast, except for a small increment in IL6 expression, no signiﬁcant
increase in pro-inﬂammatory gene expression was detected in the liver
of ob/ob mice at 5 weeks of age (Figure 2E). Altogether, these results
are consistent with the human data depicted in Figure 1 and indicate a
positive correlation between hyperinsulinemia and AT inﬂammation, in
contrast to that seen in the liver.
3.2. Reduction of hyperinsulinemia ameliorates AT inﬂammation
and improves insulin sensitivity in obese mice
We next examined whether obesity-associated hyperinsulinemia in-
creases pro-inﬂammatory cytokines and macrophage expansion in AT.
To address this question, we treated ob/ob mice with a low-dose
regimen of streptozotocin, a widely used agent that ablates b-cells,
to moderately decrease insulin secretion and circulating insulin levels
(Figure 3A). Streptozotocin treatment signiﬁcantly reduced pancreatic
islet size and number in ob/ob mice (Figure 3B). Consistent with these
observations, circulating insulin and C-peptide levels were reduced
w40% in streptozotocin treated ob/ob mice (Figure 3C). Moreover, no
signiﬁcant alteration in body weight, adiposity or blood glucose levels
were observed in ob/ob mice treated with streptozotocin under this
particular regiment (Supplementary Figure S1AeS1C).
To investigate whether obesity-induced hyperinsulinemia contributes
to the chronic low-grade inﬂammation of obese AT, we assessed the
expression of inﬂammatory cytokines/chemokines and macrophage
markers in the AT of control and ob/ob mice treated with or without
streptozotocin. As shown in Figure 3D and F, lowering circulating in-
sulin levels by w40% resulted in reduced mRNA expression of pro-
inﬂammatory markers such as CCL2, Tnfa, IL6, IL1b and Emr1 in
the AT, but not in liver of obese mice (Figure 3F). Moreover, protein
immunoblot analysis to detect MCP-1 and TNFa levels in AT further
conﬁrmed these results (Figure 3E). Additionally, immunohistochem-
istry analysis of the AT revealed that streptozotocin treatment of ob/ob
mice signiﬁcantly decreased macrophage content in the AT as
assessed by the reduced presence of crown-like structures
(Figure 3G). Taken together, these results indicate that moderate in-
sulin deﬁciency induced by streptozotocin treatment reduces the
chronic low-grade inﬂammation in AT in ob/ob mice.
To further investigate the role of hyperinsulinemia in obesity-induced
AT inﬂammation, we also used an alternative inhibitor of insulin
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secretion, diazoxide, to reduce circulating insulin levels in diet-induced
obese mice and examined its effects on AT inﬂammation. This drug is
often used clinically to inhibit insulin secretion in patients suffering
from conditions such as insulinoma and congenital hyperinsulinism
[51e53]. As shown in Figure 4A and B, serum concentrations of c-
peptide and insulin were signiﬁcantly raised in plasma of HFD-fed
mice, but not in mice fed with HFD-containing diazoxide. Moreover,
isocaloric feeding of HFD to control and diazoxide-treated mice did not
affect body weight gain, adiposity, or fasting glucose levels
(Figure 4CeF).
We then examined whether the diazoxide-mediated reduction of
hyperinsulinemia in obese mice affects AT-inﬂammation. Inﬁltration of
inﬂammatory macrophages into WAT was markedly lower in
diazoxide-treated mice compared to controls, as assessed by H&E
(Figure 4G) as well as macrophage marker staining (data not shown).
This diazoxide-dependent reduction in the appearance of macrophage
crown-like structures was associated with a marked attenuation in the
expression levels of inﬂammatory genes, such as CD68, Tnfa and
CCL2, in AT (Figure 4H). Altogether, the results shown in Figures 3 and
4 are consistent with the hypothesis that obesity-associated hyper-
insulinemia contributes to the development of low-grade chronic
inﬂammation in AT.
To examine whether reducing WAT inﬂammation through decreasing
circulating insulin levels is associated with improved systemic insulin
sensitivity in obese mice, we performed insulin tolerance tests in
control and streptozotocin-treated ob/ob mice. Fasting insulin levels
showed a 40e50% reduction in mice treated with streptozotocin
compared to control treated mice (data not shown). Streptozotocin-
treated ob/ob mice were signiﬁcantly more insulin sensitive in
lowering blood glucose levels than untreated ob/ob mice (Figure 5A).
Consistent with these results, streptozotocin-treated mice also showed
a signiﬁcant increase in the abundance of the insulin receptor (IR) and
Akt, as well as enhanced insulin-stimulated Akt phosphorylation
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Figure 1: Adipose tissue inﬂammation correlates with circulating insulin levels e (A) Expression levels of CCL2 and IL6 mRNA in AT positively correlated with circulating
insulin levels, but not BMI, in obese subjects. Depicted are results from 36 obese subjects. Multivariate linear regression analysis was also carried out and conﬁrmed a signiﬁcant
correlation between insulin and CCL2 (P < 0.05) and IL1b (P < 0.05) with a trend for IL6 (P ¼ 0.07). (B) Correlation of AT cytokines and (C) macrophage content (% macrophages)
with serum insulin levels in mice fed a HFD for 1e4 weeks; the value of the Pearson’s correlation coefﬁcient and P values are shown. Each data point represents the fold change of
mRNA levels (B) or the % of macrophages (C) in murine epididymal fat pads compared to control chow fed mice at different serum insulin concentrations. N ¼ 5e6 mice/group.
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independent of changes in hepatic steatosis. These results suggest
that a reduction in circulating insulin levels in obese mice attenuates
AT inﬂammation and increases systemic insulin sensitivity.
To further examine the metabolic effects of decreased circulating in-
sulin levels and AT inﬂammation, we measured lipogenic gene
expression and conversion of 14C-glucose into TG-fatty acids. As
illustrated in Figure 5C, several lipogenic transcriptional factors and
enzymes that function in the DNL pathway were suppressed in AT from
ob/ob mice compared to lean controls. Remarkably, the streptozotocin
treatment restored expression of lipogenic genes in the AT from ob/ob
mice in a dose-dependent manner (Figure 5C). In agreement with the





Figure 2: Time course of hyperinsulinemia, inﬂammation, glucose intolerance and insulin resistance in ob/ob mice. (A), Body weight of C57BL/6J wild type (WT) or ob/ob
mice (8 per group) from 4 to 11 weeks of age. (B), Glucose tolerance test (GTT) in WT and ob/ob animals at 5, 7 and 11 wks of age. Also shown is the area under the curve for the
glucose tolerance test. N ¼ 8 at mice per time point. (C) Insulin tolerance test (ITT) in WT and ob/ob mice at 7 weeks of age. (D) Plasma insulin levels at 5, 7 and 11 weeks of age
in WT and ob/ob mice. WT mice from each age group were pooled as insulin levels over the time course did not differ in WT mice. (E) Inﬂammatory gene expression in sub-
cutaneous (SubQ), epididymal (Epi) AT and livers from C57BL/6J WT or littermate ob/ob mice at 5, 7 or 11 weeks of age; N ¼ 4e5 mice per group.Data are presented as
mean þ/ SE and were compared to appropriate controls by Student’s T-test. *; P < 0.05, ****; P < 0.0001, #; P < 0.01, @; P < 0.001.
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expression were also restored to WT levels (data not shown). More-
over, glucose conversion into fatty acids in AT was increased by 4 fold
following streptozotocin treatment of ob/ob mice (Figure 5D). In
contrast, the expression levels of lipogenic genes in liver were not
affected by the streptozotocin treatment (Figure 5E). These data are in
agreement with the hypothesis that hyperinsulinemia drives obesity-








Figure 3: Streptozotocin treatment reduces hyperinsulinemia and attenuates inﬂammation in AT from ob/ob mice. (A) Time line of streptozotocin administration. Five-
week-old ob/ob mice were i.p. injected once a day for 5 days with the indicated dose of streptozotocin or control citrate buffer. Two weeks later, an additional single dose of
streptozotocin (200 mg/kg) was i.p. injected. (B) Pancreata from 12-week-old mice were isolated, ﬁxed, sectioned, and stained with anti-insulin antibody. Shown are islets and
insulin-stained b-cells. Images are representative of mice in each group. (C) Insulin and c-peptide serum levels in WT, ob/ob and streptozotocin (STZ)-treated ob/ob mice. (D)
Adipose or (F) liver tissues from WT and ob/ob mice treated or not with the indicated doses of streptozotocin were harvested and mRNAs measured by quantitative RT-PCR analysis.
Depicted are the relative expression levels of indicated pro-inﬂammatory genes. (E) Representative immunoblot of CCL2 and TNFa proteins in AT lysates from 12-week-old WT or
ob/ob mice treated with indicated doses of streptozotocin. (G) H&E staining of AT sections, with crown-like structures (indicated by arrows) from WT and control or STZ-treated ob/
ob mice. Graphs show the mean  SEM; N ¼ 5e6 per group, compared with chow controls, by Student’s t test *P < 0.05; **P < 0.01; ****P < 0.0001.
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3.3. Hyperinsulinemic-euglycemic clamp induces inﬂammation of
AT but not liver
We next examined whether hypersulinemia could enhance AT
inﬂammation independent of obesity. To address this question we
performed a hyperinsulinemic-euglycemic clamp on wild type 6e7
week old lean male mice. In these experiments, mice were infused
with saline or insulin for up to 2 h, while remaining euglycemic.
Following the clamp, tissues were harvested and the expression levels
of pro-inﬂammatory genes in AT in response to high the dose of insulin
analyzed. As shown in Figure 6A, CCL2, IL6 and IL1b mRNA expression
levels in AT were upregulated 2e3 fold by the hyperinsulinemic
condition, independent of insulin receptor levels (Supplementary
Figure 3). Thus, this data indicates that increasing circulating levels
of insulin enhances AT inﬂammation, independent of obesity.
3.4. Chronic insulin treatment requires Erk but not Akt to induce
CCL2 expression in cultured adipocytes
The results illustrated in Figures 3e5 suggest that the chronic
hyperinsulinemia observed in obesity contributes to increased







Figure 4: Diazoxide treatment ameliorates hyperinsulinemia and AT inﬂammation in diet-induced obese mice. 8-week-old WT C57BL/6J mice were fed a 60% HFD for 4
weeks, containing 1.125 mg/kg diazoxide or not. (A) c-Peptide, (B) insulin and (C) glucose serum levels were measured in chow, HFD and HFD-containing diazoxide fed mice. (D)
Body weight was measured, along with (E) subcutaneous and (F) epididymal fat mass expressed as percentage of body weight. (G) H&E staining of AT sections, depicting crown-
like structures from control chow, HFD and HFD with diazoxide fed mice. Images are representative of 6e8 mice per group. (H) Relative expression levels of indicated pro-
inﬂammatory genes in AT from chow, HFD or HFD with diazoxide-treated mice. Graphs show the mean  SEM. N ¼ 5e6 per group, compared with chow controls, by Stu-
dent’s t test. *P < 0.05; **P < 0.01; ***P < 0.001.
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to the increased numbers of macrophages or to increased cytokine
expression levels, either in the immune cells or in the adipocytes
themselves. To further investigate whether chronic insulin treatment
can stimulate CCL2 expression in adipocytes, we performed a time
course of high insulin treatment in mature, differentiated 3T3-L1 ad-
ipocytes. Treatment with 1 mM insulin led to a 10-fold increase in CCL2
mRNA levels within 6 h (Figure 6C). Similar results were obtained when
mature adipocytes were treated with 100 nM insulin, although this
concentration is still above physiological levels (Supplementary
Figure S2A).
Insulin activates the mitogenic MAPK/ERK protein kinases and the
metabolic PI3k-Akt pathways. To determine which downstream
signaling pathway mediates the insulin-induced expression of
inﬂammatory genes in adipocytes, we pre-treated cells with either an
ERK or Akt inhibitor. Strikingly, pre-treatment of 3T3-L1 adipocytes
with the ERK inhibitor PD98059 ablated the insulin-induced increase in
inﬂammatory gene expression (Figure 6B). In contrast, speciﬁc inhi-
bition of Akt activation with the inhibitor MK2206 had no effect on
inﬂammatory gene expression (data not shown). These results indicate
that chronically elevated insulin promotes CCL2 expression in mature
adipocytes in an ERK-dependent manner.
Interestingly, the transcription factor Mlxipl (ChREBP), known to
regulate AT-DNL [23], was also strongly suppressed by chronic insulin
treatment of mature 3T3-L1 adipocytes (Supplementary Figure S2).
Furthermore, Slc2a4 (GLUT4) and other lipogenic enzymes, such as






Figure 5: Reduction of hyperinsulinemia improves insulin sensitivity in ob/ob mice and restores AT DNL. (A) Insulin tolerance test (ITT) was performed by i.p injecting 1 U/
kg insulin in pair fed ob/ob mice treated or not with streptozotocin. The area under the curve was also calculated. (B) AT explants from WT and ob/ob mice treated or not with the
indicated doses of streptozotocin were stimulated with insulin for 30 min. Tissue lysates were then immunobloted for insulin receptor (IR), Akt, phospho-Akt (pAkt) and actin as a
loading control. RT-PCR analysis to determine the relative levels of mRNA of indicated lipogenic genes in adipose (C) or liver (E) tissue from C57BL/6J WT and ob/ob mice treated or
not with indicated doses of streptozotocin. (D) Insulin-stimulated [14C]-glucose conversion into TG-fatty acids was measured in subcutaneous AT explants from ob/ob mice treated
or not with indicated doses of streptozotocin. Graphs show the mean  SEM. N ¼ 6e9 per group, compared with ob/ob controls, by Student’s t test. *P < 0.05; **P < 0.01.
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adipocytes exposed to chronically elevated insulin levels
(Supplementary Figure S2). Altogether, these data indicate that adi-
pocytes, when chronically exposed to high doses of insulin, increase
expression of the inﬂammatory gene CCL2, while reducing the
expression of lipogenic genes.
4. DISCUSSION
The major ﬁnding of this study is that the extent of AT inﬂammation,
including increased macrophage expansion and expression of cyto-
kines, is signiﬁcantly promoted by high circulating insulin in both lean
and obese mice. We found that the high levels of cytokine expression
in gonadal AT of both diet-induced and genetically obese mice are
alleviated by lowering the hyperinsulinemia (Figures 3 and 4) and can
be induced even in lean mice by insulin infusion (Figure 6). Previous
studies from our laboratory and others have demonstrated major ef-
fects of AT inﬂammation, both deleterious [15] and beneﬁcial
[16,17,54,55], on AT metabolism and whole body insulin sensitivity
and glucose tolerance. Thus, these present ﬁndings showing insulin
induces AT inﬂammation combined with the well-known high inci-
dence of hyperinsulinemia in obesity suggest that this effect of insulin
is of high physiological signiﬁcance. Importantly, our results indicate
that reducing circulating insulin levels in both genetic and diet-induced
obese mice protects against AT dysfunction and improves systemic
insulin sensitivity (Figures 3e5). While AT inﬂammation and
dysfunction are well known to be associated with obesity and systemic
insulin resistance, the factor(s) that initiate and drive AT inﬂammation
and disrupt adipocyte function have not been resolved. Taken together,
these data indicate that insulin itself is a major contributing factor in
driving AT inﬂammation in genetic and HFD induced obesity in mice.
The data presented here on the relationship between hyperinsulinemia
and AT inﬂammation using obese mice reinforce similar suggestive
experiments that have been performed on human subjects. For
instance, a recent study by Jansen et al. demonstrated that insulin
therapy in type 2 diabetic patients was associated with enhanced
cytokine production [44]. Furthermore, hyperinsulinemic-euglycemic
clamp studies performed in humans have demonstrated an exacer-
bated inﬂammatory response following insulin infusion in insulin-
resistant patients [41,43]. The ﬁndings reported here are in agree-
ment with these previous studies and further support a role for
hyperinsulinemia as an important pro-inﬂammatory factor that pro-
motes chronic AT inﬂammation and adipose dysfunction, both in obese
humans and mice.
The contribution of insulin itself in promoting increased adiposity and
exacerbating the insulin resistance linked to obesity has been previ-
ously proposed [56e60]. These earlier data suggested that insulin
directly downregulates insulin receptor expression and interferes with
its own signaling [58e61]. However, the cellular mechanism for
hyperinsulinemia-induced AT dysfunction through increased inﬂam-
mation revealed in our present study had not been addressed.
Importantly, it has recently been shown that mice with deletions of
insulin gene alleles are resistant to diet-induced obesity, which would
be expected to decrease AT inﬂammation [56]. Moreover, reducing
insulin levels with the K-ATP channel agonist diazoxide reduces
adiposity in humans [62]. Additionally, it has been demonstrated that
diazoxide-induced insulin deﬁciency enhances insulin sensitivity [63]
and AT b3-adrenergic receptor expression and activity in mice [64],
although these studies did not address whether the reduction in insulin
levels also improves the chronic inﬂammation in AT. Our studies thus
establish AT inﬂammation as a novel pathway of insulin action in vivo
that acts in addition to the cell autonomous mechanism whereby its
signaling pathway is downregulated in response to loss of cell surface
insulin receptors.
Plasma insulin levels strongly correlated with inﬂammatory gene ex-
pressions in AT from obese humans and mice (Figure 1A and B).
Consistent with these results, we [13] and others [65] have reported
that inﬂammation of the omental AT is strongly associated with insulin
resistance in human obesity, even in subjects with similar body mass
index [13]. In addition, hyperinsulinemia correlates with increased AT
inﬂammation in clinical settings, including following insulin therapy in
type 2 diabetic subjects [44] and hyperinsulinemic-euglycemic clamps
in insulin resistant subjects [41,43]. Our present results show that
elevated insulin levels, independent of changes in body weight, pro-
mote AT inﬂammation, even in lean healthy mice following a
hyperinsulinemic-euglycemic clamp (Figure 6A). In addition, insulin
treatment induced a robust upregulation of CCL2 in cultured adipocytes
(Figure 6B). Importantly, we recently reported that CCL2 increases AT
immune cell content not only by recruiting macrophages into AT but
also by inducing local macrophage proliferation [66]. This increased
macrophage content and AT cytokine production likely further


























































Figure 6: Hyperinsulinemic-euglycemic clamp enhances AT pro-inﬂammatory
gene expressions in lean mice. Six week-old WT mice were fasted overnight and
subjected to a 2 h hyperinsulinemic-euglycemic clamp. Tissues were harvested for
total RNA extraction and qRT-PCR analysis. Shown are the relative mRNA expression
levels of different inﬂammatory markers in subcutaneous AT (A) or liver (B) from saline
and insulin-infused mice following a hyperinsulinemic-euglycemic clamp. (C) Chronic
insulin treatment induces CCL2 gene expression in cultured adipocytes. Mature 3T3-L1
adipocytes were pretreated for 30 min with vehicle (DMSO) or ERK inhibitor PD98059
(50 mM). Cells were then treated with or without 1 uM insulin for the indicated period of
time. After treatments, total RNA was extracted and relative mRNA levels measured by
qRT-PCR analysis. Graphs show the mean  SEM. N ¼ 4 replicates per group. F.C is
fold change.
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exacerbates the inﬂammatory response in vivo. Together, these data
suggest that hyperinsulinemia itself directly drives increased AT
inﬂammation, perhaps in part by enhancing macrophage proliferation.
Many studies have demonstrated that the DNL pathway is suppressed
in AT of long-term obese humans and rodents [24,25,27,30,31]. In our
studies, the reduction in AT inﬂammation upon decreasing circulating
insulin levels was associated with enhancing adipose DNL, insulin
signaling and systemic insulin sensitivity (Figures 3e5). It is known
that treatment of cultured adipocytes with pro-inﬂammatory cytokines
such as TNFa induces insulin resistance and inhibits adipocyte tran-
scription factors such as PPARg that control DNL enzymes
[32,33,35,36]. It is therefore tempting to hypothesize that reducing the
level of insulin in obese mice restores the attenuated AT-DNL in obesity
as a consequence of the reduced AT inﬂammation. In turn, the
improved AT-DNL pathway may further act to enhance systemic insulin
sensitivity, potentially through the biosynthesis of AT lipokines
[21,22,67]. Interestingly, the results depicted in Figures 3e5 indicate
that only a moderate decrease in circulating insulin levels reduces AT
inﬂammation and improves both AT insulin action on DNL and systemic
insulin sensitivity in pair fed obese mice. Moreover, stimulation of AT-
DNL through either AT speciﬁc overexpression of GLUT4 in mice or
deletion of the AT lipid chaperone aP2, improves glucose tolerance and
insulin sensitivity [22,23]. These studies are in agreement with our
data and support the concept that whole body insulin sensitivity and
adipocyte DNL are highly correlated. Although it has been shown that
dietary lipid oversupply can block AT-DNL, whether this is a direct
effect or secondary to enhanced lipid-induced insulin secretion is
unclear. Therefore, lowering insulin levels in obese humans may not
completely restore AT-DNL. Our data from humans and mice, however,
suggest that lowering of circulating insulin levels can reduce low-grade
chronic AT inﬂammation in obesity.
An acute anti-inﬂammatory effect of insulin was proposed via the
PI3K pathway in hepatocytes, while pro-inﬂammatory actions of in-
sulin may require ERK and JNK kinases [68]. In agreement with such
a pro-inﬂammatory effect of prolonged insulin exposure, we found
that treatment of cultured adipocytes with high insulin concentrations
upregulated the expression of inﬂammatory chemokines such as
CCL2 (Figure 6B). Moreover, we show that this insulin-stimulated
expression of CCL2 is blunted by ERK inhibition. Thus, a sustained
rise in plasma insulin, often seen in obese subjects, may induce
chemokine and cytokine production through hyper-activation of ERK
signaling. It has been proposed that Egr1, acting downstream of ERK,
may promote the inﬂammatory actions of insulin, while also inhibiting
the metabolic actions of insulin through PTEN mediated inhibition of
Akt activation [69]. Moreover, whole body deletion of Egr1 results in a
metabolically favorable phenotype, exhibiting enhanced energy
expenditure and reduced inﬂammation [70]. These mouse models
together with the data presented here suggest that chronic insulin
exposure may drive AT inﬂammation by initiating direct actions upon
adipocytes through ERK activation. Future studies will be required to
determine whether AT inﬂammation under hyperinsulinemic condi-
tions is caused by such direct effects of insulin on adipocytes versus
other non-adipose cell types present in AT, such as macrophages [71]
and T cells [72].
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